According to filings with the U.S. Securities and Exchange Commission, Neuros Medical is raising up to $64,999,994.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Neuros Medical
Neuros is a privately held company and the maker of the Altius Direct Electrical Nerve Stimulation System. Our mission is to reduce pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values, and committed to our patients and the healthcare professionals who care for them.

To learn more about Neuros Medical, visit https://www.neurosmedical.com/
Neuros Medical Linkedin Page: https://www.linkedin.com/company/neuros-medical-inc./

Contact:
David Veino, President and Chief Executive Officer
440-951-2565

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.